Back

Tafamidis to treat patients with transthyretin cardiac amyloidosis (ATTR-CM): real-world data from a tertiary centre

30 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: New insights into diagnosis of cardiac amyloidosis Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Miguel Sobral Domingues

Western Lisbon Hospital Centre, EPE, Lisbon (Portugal)

7 More presentations in this session

Presentation thumbnail
Diverse anatomical and metabolic effects of amyloid deposits in transthyretin cardiac amyloidosis revealed by 3D reconstruction of serial block face-scanning electron microscopy images
Doctor S. Saito (Shimotsuke, JP)
Abstract Slides Video
Presentation thumbnail
Trajectory and prognostic significance of conduction system disease in cardiac transthyretin amyloidosis: a european multicenter cohort study
Doctor L. Schlender (Frankfurt, DE)
Abstract Slides Video
Presentation thumbnail
Targeted screening for transthyretin cardiac amyloidosis in severe aortic stenosis: development and validation of a clinical risk score
Assistant Professor A. Antonopoulos (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Prognostic implications of Perugini Grading in a contemporary centre referral cohort undergoing evaluation for suspected cardiac amyloidosis
Ms N. Hartvig Jensen (DK)
Abstract Slides Video
Presentation thumbnail
Multimodal assessment of disease progression risk among transthyretin amyloid cardiomyopathy patients under disease-modifying therapy
Doctor J. Groeschel (Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
New insights into diagnosis of cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
12 May 2024
thumbnail
Congress Presentation
Risk prediction in ATTR-CM patients under tafamidis treatment: results from the multicentre SWISS-CARE registry
28 August 2026
thumbnail
Congress Presentation
Turning data into decisions: insights from trials and real-world experience in ATTR-CM
12 December 2025
thumbnail
Congress Presentation
Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources